Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.

Morabito M, Larcher M, Cavalli FM, Foray C, Forget A, Mirabal-Ortega L, Andrianteranagna M, Druillennec S, Garancher A, Masliah-Planchon J, Leboucher S, Debalkew A, Raso A, Delattre O, Puget S, Doz F, Taylor MD, Ayrault O, Bourdeaut F, Eychène A, Pouponnot C.

EMBO Mol Med. 2019 Aug;11(8):e9830. doi: 10.15252/emmm.201809830. Epub 2019 Jul 22.

2.

Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.

Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C.

Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29.

PMID:
30374200
3.

NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma.

Garancher A, Lin CY, Morabito M, Richer W, Rocques N, Larcher M, Bihannic L, Smith K, Miquel C, Leboucher S, Herath NI, Dupuy F, Varlet P, Haberler C, Walczak C, El Tayara N, Volk A, Puget S, Doz F, Delattre O, Druillennec S, Ayrault O, Wechsler-Reya RJ, Eychène A, Bourdeaut F, Northcott PA, Pouponnot C.

Cancer Cell. 2018 Mar 12;33(3):435-449.e6. doi: 10.1016/j.ccell.2018.02.006.

4.

NRAS-driven melanoma: A RAF can hide another.

Druillennec S, Pouponnot C, Eychène A.

Mol Cell Oncol. 2017 Jul 5;4(6):e1344758. doi: 10.1080/23723556.2017.1344758. eCollection 2017.

5.

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.

Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, Beermann F, Baccarini M, Pouponnot C, Larue L, Eychène A, Druillennec S.

Nat Commun. 2017 May 12;8:15262. doi: 10.1038/ncomms15262.

6.

B-Raf and C-Raf are required for melanocyte stem cell self-maintenance.

Valluet A, Druillennec S, Barbotin C, Dorard C, Monsoro-Burq AH, Larcher M, Pouponnot C, Baccarini M, Larue L, Eychène A.

Cell Rep. 2012 Oct 25;2(4):774-80. doi: 10.1016/j.celrep.2012.08.020. Epub 2012 Sep 27.

7.

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.

Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.

8.

Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Druillennec S, Dorard C, Eychène A.

J Nucleic Acids. 2012;2012:639062. doi: 10.1155/2012/639062. Epub 2011 Oct 5.

9.

B-raf alternative splicing is dispensable for development but required for learning and memory associated with the hippocampus in the adult mouse.

Valluet A, Hmitou I, Davis S, Druillennec S, Larcher M, Laroche S, Eychène A.

PLoS One. 2010 Dec 22;5(12):e15272. doi: 10.1371/journal.pone.0015272.

10.

Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation.

Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P, Eychene A, Lebecque S, Renno T.

J Clin Invest. 2010 Oct;120(10):3663-7.

11.

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, van den Oord JJ, Sarasin A, Bressac-de Paillerets B; EORTC Melanoma group.

Mol Oncol. 2008 Apr;1(4):425-30. doi: 10.1016/j.molonc.2008.01.002. Epub 2008 Jan 12.

12.

Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychène A.

Mol Cell Biol. 2007 Jan;27(1):31-43. Epub 2006 Oct 30.

13.

Development and characterization of ten monoclonal anti-Vpr antibodies.

Sabbah EN, Delaunay T, Varin A, Le-Rouzic E, Benichou S, Herbein G, Druillennec S, Roques BP.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):630-9.

PMID:
16831087
14.

Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator.

Sabbah EN, Druillennec S, Morellet N, Bouaziz S, Kroemer G, Roques BP.

Chem Biol Drug Des. 2006 Feb;67(2):145-54.

PMID:
16492162
15.

Cell context reveals a dual role for Maf in oncogenesis.

Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S, Felder-Schmittbuhl MP, Eychène A.

Oncogene. 2006 Mar 2;25(9):1299-310.

PMID:
16247450
16.
17.

Target specificity of human immunodeficiency virus type 1 NCp7 requires an intact conformation of its CCHC N-terminal zinc finger.

Ramboarina S, Druillennec S, Morellet N, Bouaziz S, Roques BP.

J Virol. 2004 Jun;78(12):6682-7.

18.

HIV-1 NCp7 as a target for the design of novel antiviral agents.

Druillennec S, Roques BP.

Drug News Perspect. 2000 Aug;13(6):337-49.

PMID:
12937655
19.

The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway.

Roumier T, Vieira HL, Castedo M, Ferri KF, Boya P, Andreau K, Druillennec S, Joza N, Penninger JM, Roques B, Kroemer G.

Cell Death Differ. 2002 Nov;9(11):1212-9.

20.

Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope.

Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA, Andreau K, Perfettini JL, Amendola A, Nardacci R, Leduc P, Ingber DE, Druillennec S, Roques B, Leibovitch SA, Vilella-Bach M, Chen J, Este JA, Modjtahedi N, Piacentini M, Kroemer G.

EMBO J. 2002 Aug 1;21(15):4070-80.

21.

Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2.

Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Métivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G.

J Exp Med. 2001 Feb 19;193(4):509-19.

22.

Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Kichler A, Pages JC, Leborgne C, Druillennec S, Lenoir C, Coulaud D, Delain E, Le Cam E, Roques BP, Danos O.

J Virol. 2000 Jun;74(12):5424-31. Erratum in: J Virol. 2000 Dec;74(24):12003.

23.

The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore.

Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Daugas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP, Kroemer G.

J Exp Med. 2000 Jan 3;191(1):33-46.

24.

A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Druillennec S, Dong CZ, Escaich S, Gresh N, Bousseau A, Roques BP, Fournié-Zaluski MC.

Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4886-91.

25.

Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1.

Druillennec S, Caneparo A, de Rocquigny H, Roques BP.

J Biol Chem. 1999 Apr 16;274(16):11283-8.

26.

Nucleomimetic strategy for the inhibition of HIV-1 nucleocapsid protein NCp7 activities.

Druillennec S, Meudal H, Roques BP, Fournié-Zaluski MC.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):627-32.

PMID:
10098678

Supplemental Content

Loading ...
Support Center